Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
The shortage of drugs in Russia is deepening, and is currently being observed in almost 70 regions throughout the country and forcing the local state to consider ways to resume stable supplies to local market, reports The Pharma Letter’s local correspondent. 13 August 2024
US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 7 August 2024
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
Domestic drugs and foreign drugs, the production of which is localized in Russia, will be given a priority when included in the list of vital and essential drugs (VED) and expensive drugs, according to a recent resolution signed by the Russian government, The Pharma Letter’s local correspondent reports. 1 August 2024
The Russian government has adopted a new method for determining the prices for vital and essential drugs, according to an official spokesman of Russian Minister of Health Veronika Skvortsova, reports The Pharma Letter’s local correspondent. 13 December 2018
Russian drugmaker Polysan will invest about 4 billion roubles (~$60 million) in the establishment of full-cycle production of a drug from German pharma major Bayer, according to the company, reports The Pharma Letter’s local correspondent. 13 December 2018
Activity in the pharma sector is rife in India, with mergers and acquisition deal values doubling given revived domestic and cross-border deal activity. Technology in the form of Artificial Intelligence and Big Data has also come to the aid of the pharmaceutical industry, reports The Pharma Letter’s India correspondent. 12 December 2018
Japanese biotech firm Sosei Group today announced that its board of directors, at a meeting held on December 11, 2018, approved a change in its president and chief executive (CEO). 12 December 2018
Although biosimilars have taken off in Europe, they have yet to gain traction in the USA, writes Anne Runyan, senior consultant of market access at MKO Global Partners, in an Expert View on the topic. 11 December 2018
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) has named David Ricks, the chairman and chief executive of US pharma major Eli Lilly, as its new president. 11 December 2018
Adam Schechter, president of Global Human Health (GHH) at US pharma giant Merck & Co, is stepping down from his current position as of December 31, 2018, and will be shifting to an advisory capacity to the chief executive. 11 December 2018
Following the previously-announced plans of John Milligan to step down from the top post by year-end, US biotech major Gilead Sciences has named Daniel O'Day as chairman and chief executive, effective March 1, 2019. 10 December 2018
Daniel O'Day, chief executive of Roche Pharmaceuticals and member of the Roche corporate executive committee, will be stepping down from his role as of December 31, 2018. 10 December 2018
An exclusive Expert View column written for The Pharma Letter by Thomas Cueni, International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) director general and co-chair of the APEC Biopharmaceutical Working Group on Ethics. 6 December 2018
Drug-making is sometimes pictured as one of the last surviving “traditional” industries, successfully resisting waves of change that have overtaken other businesses. 5 December 2018
Leading Russian pharmaceutical companies have called on the national government to provide additional support that will be used for the launch of full cycle production and the increase of exports, according to recent statements of producers and some senior officials of the Russian Ministry of Health, reports The Pharma Letter’s local correspondent. 3 December 2018
Leading Russian and foreign drugmakers operating in Russia will be able to launch their drugs more quickly in the local pharmaceutical market, thanks to the recent amendments approved by the Council of Federation, the 3 December 2018
Ireland-headquartered pioneering inflammasone company Inflazome has announced the appointment of Dr Thomas Jung as its chief medical officer. 30 November 2018
Netherlands-headquartered Mylan’s (Nasdaq: MYL) flagship oral solids facility getting a US Food and Drug Administration warning letter is being viewed as an advantage Indian drug majors, reports The Pharma Letter’s India correspondent. 30 November 2018
Charlotte Tillett, partner, and Emily Hocken, trainee, at Stevens & Bolton, offer an Expert View on the significance of the UK Supreme Court ruling in Warner-Lambert (WL) v Generics relating to WL’s best-selling pain relief drug, Lyrica (pregabalin). 28 November 2018
Israel and USA-based biotech Anchiano Therapeutics today announced the appointment of David Kerstein, as the company’s new chief medical officer (CMO). 27 November 2018